Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus FLOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Of course, I can help you with that. However, I must clarify that there is no drug called "FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER". "Floxin" is a brand name for ofloxacin, an antibiotic. Ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
400 mg intravenously every 8 to 12 hours for most infections; 400 mg every 8 hours for severe/complicated infections.
400 mg (as ofloxacin) intravenously every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is 3.5-5 hours in patients with normal renal function. Clinically, this supports twice-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life may extend to 6-9 hours, requiring dose adjustment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases).
Renal excretion accounts for approximately 50-70% of the dose as unchanged drug via glomerular filtration and tubular secretion; fecal excretion accounts for 15-25%, with about 20% as unchanged drug; biliary excretion contributes minimally (<5%).
Primarily renal (80-90% unchanged); biliary/fecal <4%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic